TBPH
Theravance Biopharma, Inc.
NASDAQ · KYHealthcareBiotechnology
$16.81-0.71%
Price as of Jul 20, 2026
TBPH profitability
Theravance Biopharma, Inc. profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- 80.4%
- EBITDA margin
- 129.8%
- EBIT margin
- 0.1%
- Net margin
- 104.3%
- Free cash flow margin
- 244.8%
Returns
- Return on equity
- 39.4%
- Return on assets
- 24.3%
- Return on invested capital
- 0.0%
- Asset turnover
- 0.23x
Cash efficiency
- Cash from operations
- $268.8M
- Cash per share
- $7.66
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.